Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Editas Medicine (NQ: EDIT )

7.110 -0.340 (-4.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,952,564
Open 7.370
Bid (Size) 7.120 (2)
Ask (Size) 7.450 (1)
Prev. Close 7.450
Today's Range 7.000 - 7.490
52wk Range 7.000 - 21.59
Shares Outstanding 68,970,188
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket
Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it. 
Via InvestorPlace
Thinking of Buying Biotech Stocks? Do These 3 Things First
It's better to plan ahead than to get caught by surprise. 
Via The Motley Fool

Performance

YTD
-15.76%
-15.76%
1 Month
-21.35%
-21.35%
3 Month
-14.85%
-14.85%
6 Month
-44.02%
-44.02%
1 Year
-62.10%
-62.10%

More News

Read More
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linea Aspesi as Chief People Officer
From Editas Medicine, Inc.
Via Globe NewsWire
Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates
From Editas Medicine, Inc.
Via Globe NewsWire
Editas Medicine Earnings Preview
Via Benzinga
Top CRISPR Stocks
Via Talk Markets
Why Editas Medicine Stock Charged Higher in January
Via The Motley Fool
Expert Ratings for Editas Medicine
Via Benzinga
These 2 Biotech Stocks Could Soar in the Next Bull Market
Via The Motley Fool
Is Exact Sciences or Editas Medicine the Better Growth Stock to Own in 2023?
Via The Motley Fool
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2022 Results and Corporate Update
From Editas Medicine, Inc.
Via Globe NewsWire
3 No-Brainer Stocks to Buy Right Now for Less Than $25
Via The Motley Fool
Why Editas Medicine's Shares Jumped This Week
Via The Motley Fool
Why Shares of Editas Medicine Jumped This Week
Via The Motley Fool
Shoreline Biosciences Acquires Editas' iNK Cell Franchise, Related Gene Editing Technologies
Via Benzinga
Analyst Expectations for Editas Medicine's Future
Via Benzinga
Why Editas Medicine Stock Is Sliding Today
Via The Motley Fool
Is Editas Medicine Stock a Buy Now?
Via The Motley Fool
3 CRISPR Stocks to Buy Now Or You’ll Be Kicking Yourself Later
Via InvestorPlace
Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023
Via Benzinga
7 CRISPR Stocks With the Best Long-Term Potential
Via InvestorPlace
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
Via MarketBeat
Topics Workforce
Exposures Layoff Product Safety
Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies
From Editas Medicine, Inc.
Via Globe NewsWire
3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.